Hoffmann-la Roche Inc.

Medicines for Malaria Venture (mmv)

Genentech, Inc.

Medicines for Malaria Venture Mmv International Centre Cointrin

F. Hoffmann-la Roche Ag

Mmv Medicines for Malaria Venture

Medicines for Malaria Venture

Medicines for Malarial Venture Mmv

Hugues Matile

Jacques Chollet

Jonathan L Vennerstrom

Yuxiang Dong

William Charman

Sannah Zoffmann Jensen

Stephan Roever

Paul Hebeisen

Matthew Wright

Xiaofang Wang

Kamaraj Spiraghavan

Maniyan Padmanilayam

William N Charman

Christian N Hubschwerlen

Christoph Ullmer

Kerstin Jahn-Hofmann

Thilo Enderle

Susan A Charman

Haiyan Wang

Doris Roth

Jeremy Beauchamp

Cristiano Migliorini

Sergio Wittlin

Darren J Creek

Anita Dreyer

Lin Zhou

William N Chapman

Yuangqing Tang

Yuanqing Tang

Sannah Zoffman Jensen

Robert George Ridley

Jawad Alzeer

Yatendra Kumar

Gyan Chand Yadav

Kamaraj Sriraghavan

Sannah Jensen Zoffmann

The present invention provides expression vectors for cell-surface expression of polypeptides comprising a transmembrane domain of glycophorin A.

Expression vectors for cell-surface expression of polypeptides comprising a transmembrane domain of glycophorin A

The present invention relates to an in vitro method for detecting cAMP or cGMP comprising a) contacting a mixture with a complex of a tracer and a dequencher, wherein the tracer is a fluorophore covalently linked to a cAMP quencher, and b) measuring the change in fluorescence. Furthermore, the present invention relates to the use of said method for determining the cAMP or cGMP concentration in the mixture, for determining the activity of a receptor wherein the signal transduction of the receptor comprises cAMP or cGMP and for screening of a ligand for such a receptor.

Method of detection of cAMP and cGMP via a fluorophore and dequencher complex

The present invention relates to compounds of the formula wherein A, A, Aand Rto Rare defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

Heteroarylmethyl amides

The present invention relates to an antibody directed to a beta cell marker protein, in particular to an antibody directed to the protein TMEM27.

Tmem27 antibody

The present invention provides an antibody directed to an epitope of a G-protein coupled receptor, wherein the antibody binds to the extracellular N-terminal region of the receptor and the binding of the antibody to the G-protein coupled receptor induces receptor internalization in cells.

Antibodies directed to mGluR7

A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites. The compounds of the invention unexpectedly provide a single-dose cure for malaria, as well as prophylactic activity against the same. The compounds are also active against schistosomiasis and cancer.

Dispiro 1,2,4-trioxolane antimalarials

A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably substituted at the 4-position. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites.

Spiro and dispiro 1,2,4-trioxolane antimalarials

Spiro and dispiro 1,2,4-trixolane antimalarials

A means and method for treating malaria using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl or spiropiperidyl ring on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably functionalized or substituted at the 4-position or a spiropiperidyl ring that is functionalized or substituted at the nitrogen atom. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites.

The present invention relates to compounds having the formulae ##STR1## wherein R, R.sup.1, R.sup.6, R.sup.7, Rn.sup.8, X, and Z are defined herein, which are useful in the treatment or prophylaxis of malaria. The compounds of the present invention are especially useful in the treatment or prophylaxis of chloroquine-sensitive and chloroquine-resistant malaria.

.beta.-Alkoxyacrylates against malaria

Growing community of inventors

Basel, Switzerland

Hugues Matile